3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Multiple Myeloma
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Fanconi Anemia
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
9
Specimen Handling
8
Cisplatin
5
Cetuximab
5
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cemiplimab
3
Radiotherapy
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
(225)Ac-DOTA-c(RGDyK)
3
pembrolizumab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
temsirolimus
1
niraparib
1
ipatasertib
1
durvalumab
1
dostarlimab
1
cabozantinib
1
atezolizumab
1
Valproic Acid
1
Ultrasonography
1
Transurethral Resection of Bladder
1
Tramadol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mouth Neoplasms
×
Afatinib
×
30 days
×
Clear all
NCT06897735
2026-06-03
EDDIS-a1
Petrov, Andrey
Phase 1
Terminated
4 enrolled